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it remains prudent to target lipid 
levels according to established 
guidelines. Of course, it also re-
mains important to recommend 
increased exercise, healthy food 
choices, and portion control and 
to help manage weight in patients 
with prediabetes levels of glyce-
mia or metabolic syndrome.
Studies to define the risks of 
statin-induced diabetes and its 
underlying mechanisms are clear-
ly necessary. But until more data 
are available, clinicians should 
monitor glucose or glycated hemo-
globin in patients with multiple 
risk factors for diabetes who take 
statins, but they should continue 
to prescribe statins when indicat-
ed as part of a multifactorial ap-
proach to managing cardiovascu-
lar risk.
Disclosure forms provided by the author 
are available with the full text of this arti-
cle at NEJM.org.
From Harvard Medical School and the Sec-
tion of Clinical, Behavioral, and Outcomes 
Research, Joslin Diabetes Center — both in 
Boston.
This article (10.1056/NEJMp1203020) was 
published on April 25, 2012, at NEJM.org.
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Statins: Time to Reassess Benefits and Risks?
Measles in the 21st Century
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Barely 20 years ago, such a high proportion of childhood 
deaths globally was attributable 
to measles that the going esti-
mate of more than 1 million 
measles-related deaths per year 
was almost certainly an underes-
timate. Pediatric wards in the de-
veloping world were filled with 
patients with mea-
sles and its compli-
cations, and measles 
continued to be a ma-
jor cause of blindness 
globally. All this occurred de-
spite the remarkable progress 
that had been achieved during the 
1980s in bringing routine immu-
nizations, including a single dose 
of measles vaccine, to the poor-
est countries of the world, culmi-
nating in the achievement of the 
global Universal Childhood Im-
munization goals in 1990. In the 
United States, where measles had 
been effectively controlled since 
1982, a minor resurgence of the 
disease occurred between 1989 
and 1991, resulting in 123 deaths 
and more than 11,000 hospital-
izations. Almost half of all cases 
were in older children or adults. 
The subsequent introduction of 
a two-dose vaccination strategy 
led to the elimination of measles 
in the United States by 2000, al-
though imported cases continue 
to feed small outbreaks. In 2011, 
90% of the 222 cases reported in 
the United States were associated 
with imported cases.
During the 1990s, routine im-
munization stagnated in many 
parts of the developing world, 
especially Africa. The increasing 
emphasis on controlling poliovi-
rus through focused campaigns 
may have been a factor in this 
stagnation, although it did en-
able some countries to undertake 
measles-vaccination campaigns 
that led to variable levels of con-
trol. By 2000, the countries of 
the African Region of the World 
Health Organization (WHO) were 
reporting more than 500,000 
measles cases per year.1 Global 
measles-related deaths were esti-
mated at more than 700,000 per 
year, but there was considerable 
disagreement over these modeled 
estimates, and many experts be-
lieved they were too high. Between 
2000 and 2008, measles control 
improved markedly in all regions 
(see the interactive graphic, avail-
able with the full text of this arti-
cle at NEJM.org). Indigenous mea-
sles transmission was interrupted 
in the Americas by 2002, and the 
number of reported cases in Afri-
ca in 2008 was less than 10% of 
the 2000 level, despite improved 
reporting methods.2 Control was 
being achieved through the addi-
tion of a second dose of measles 
vaccine, either within the routine 
schedule for countries with well-
functioning programs or in tar-
geted campaigns.
After 2005, a new pattern be-
gan to emerge, with some richer 
countries failing to maintain suf-
ficient vaccination coverage to 
control the disease. In Western 
Europe, Switzerland, Germany, 
France, and Britain reported con-
tinuing measles transmission and 
declining vaccination coverage, 
associated with sensationalized 
reports of adverse events, objec-
tion to immunization among 
certain groups, and a marked in-
            An interactive 
graphic showing 
incidence and vaccination 
rates is available 
at NEJM.org 
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crease in the activities of antivac-
cination lobbying groups. During 
the same period, China and Japan 
brought their measles incidence 
down to very low levels.
Regardless of what the true 
mortality rate was in 2000, there 
is no doubt that by 2008 global 
measles-related deaths had de-
clined markedly, to an estimated 
164,000.3 Measles-control activi-
ties had been outstandingly suc-
cessful. It seemed to be only a 
matter of time before the world 
could feasibly take on the task of 
measles eradication. Advocates 
pointed to the success in the 
Americas as evidence of the fea-
sibility of eradication, though op-
ponents highlighted the extreme 
infectiousness of the virus, the 
lack of understanding of measles 
epidemiology, the survival of the 
virus in remote areas, and the 
seemingly insurmountable tech-
nical and financial difficulties 
facing polio-eradication efforts.
By 2008, the WHO and part-
ners were struggling with polio 
eradication, which had missed 
its 2000 global target. On scien-
tific and public health grounds, 
the feasibility, desirability, and 
timing of measles eradication 
should not be dependent on the 
ongoing polio-eradication effort. 
In practice, however, the two ef-
forts are inextricably linked. Be-
cause the same donors that fund 
polio-eradication programs will 
be called on to support measles 
eradication, the shifting of re-
sources could jeopardize polio-
eradication efforts. Some argue 
that if polio eradication is really 
feasible, it should be completed 
before measles-eradication efforts 
are launched; yet by 2008, con-
tinuing polio transmission in In-
dia, Nigeria, Pakistan, and other 
countries where the virus was 
endemic was leading to growing 
skepticism about the feasibility of 
eradication.
Meanwhile, since 2008, the 
measles genie seems to have 
slipped out of the bottle in many 
regions. In Africa, measles con-
trol has deteriorated markedly, 
with the number of confirmed 
cases increasing from around 
37,000 in 2008 to more than 
172,000 in 2010.1 The distribu-
tion of cases follows the expected 
epidemiologic patterns: countries 
that had previously achieved good 
control report many cases in older 
children and adults, and countries 
with historically poor control, such 
as Nigeria, report that most cases 
occur in infancy and early child-
hood. A common feature in devel-
oping countries is the substantial 
proportion of cases occurring in 
the first year of life. The situa-
tion in Europe continues to be 
concerning as well, with measles 
incidence increasing in many in-
dustrialized countries. France 
alone reported over 15,000 mea-
sles cases, including 6 deaths, in 
2011, according to the WHO.
In Africa, funding for measles 
control has fallen away since 
2008, and the frequency and, in 
some cases, effectiveness of cam-
paigns have declined. In Europe 
and parts of southern Africa, cer-
tain religious groups refuse im-
munization, and the result is con-
centrated pools of susceptible 
persons. In some African coun-
tries, outbreaks have occurred a 
short time after the implementa-
tion of campaigns, which sug-
gests that the campaigns’ quality 
has declined and that reported 
coverage may be exaggerated. To 
ensure that every child receives 
two doses of measles vaccine, 
both routine service delivery and 
campaigns must strive to achieve 
100% coverage. Epidemiologic 
analysis is critical in order to 
determine the appropriate age 
groups to be covered in cam-
paigns. In most countries, the 
incidence of disease is highest 
among children in the first year 
of life, whereas the proportion of 
cases occurring in children older 
than 5 years of age and in adults 
varies from country to country.
Infants under 9 months of age 
are traditionally regarded as too 
young to be vaccinated. Increas-
ingly, however, babies are being 
born to mothers with minimal 
measles immunity, often owing 
to minimal natural boosting af-
ter childhood immunization. Such 
mothers pass less-protective im-
munity to their infants, who are 
therefore protected for a shorter 
period, and it has been proposed 
that these infants be vaccinated at 
a younger age.4 A recent trial of 
measles immunization at 4 months 
of age in Guinea-Bissau showed 
adequate protective efficacy.5 If 
these results can be replicated 
elsewhere, it would be appropri-
ate to revisit the recommended 
age of first measles vaccination 
in order to close the current win-
dow of susceptibility.
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An African child with severe measles  
on day 10 of the disease.
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Although global measles con-
trol seems to be struggling, the 
polio situation is looking some-
what more promising. On Janu-
ary 13, 2012, India reported that 
it had been 12 months since the 
last wild-virus poliomyelitis case 
was confirmed in that country. 
However, 2011 saw increased 
numbers of new polio cases in 
Pakistan (197), Chad (131), Nigeria 
(57), and Afghanistan (80), accord-
ing to the Global Polio Eradica-
tion Initiative. Polio eradication re-
mains an elusive target, although 
there is growing optimism that it 
may eventually be achieved. If and 
when that occurs, the overall fi-
nancial costs plus the opportu-
nity costs will have exceeded the 
initial estimates many times over 
— a point that is not likely to be 
lost on funding agencies. These 
figures will be essential for cal-
culating realistic costs of mea-
sles eradication, which should be 
analyzed and weighed against the 
substantial future health and eco-
nomic benefits such an initiative 
could bring. In the shorter term, 
however, until greater measles 
control is achieved, particularly in 
Western Europe and Africa, health 
professionals in the United States 
can anticipate more small out-
breaks among susceptible groups 
due to imported measles virus.
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